Skip to search formSkip to main contentSkip to account menu

1 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

Known as: Cosentyx 150 MG/ML 1ML Prefilled Syringe, SECUKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION [COSENTYX]_#2, 1 ML Cosentyx 150 MG/ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

12 relations
1 ML secukinumab 150 MG/ML Auto-Injector [Cosentyx]CosentyxHISTIDINE MONOHYDROCHLORIDE MONOHYDRATEHistidine

Broader (2)

1 ML secukinumab 150 MG/ML Prefilled SyringeCosentyx Injectable Product

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Interleukin-17A-Inhibitor bei axialer Psoriasis-Arthritis wirksam
Mit dem Interleukin(IL)-17A-Inhibitor Secukinumab (Cosentyx®) wurde erstmals ein Biologikum bei axial ausgeprägter… 
2019
2019
Severe colitis complicating secukinumab (Cosentyx®) therapy
of acute myelogenous leukaemia (AML) was evaluated by the dermatology department because of a 1-month history of progressive… 
2018
2018
THU0319 Overall safety of 7-week secukinumab exposure during pregnancy in women with psoriatic arthritis
Background Psoriatic arthritis (PsA) often affects women of reproductive age. Secukinumab (SEC), a monoclonal antibody against… 
2018
2018
Clinical outcomes in patients on secukinumab (Cosentyx®) within a specialist psoriasis clinic: a single centre, retrospective cohort study
Secukinumab, a fully human anti-IL-17A monoclonal antibody, is a highly effective therapy for chronic plaque psoriasis. Up to 81… 
Review
2017
Review
2017
Secukinumab (Cosentyx°) and plaque psoriasis.
  • Prescrire international
  • 2017
  • Corpus ID: 73417787
Review
2017
Review
2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
BACKGROUND Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic… 
2016
2016
Aknetherapie: Vorteile durch innovative Fixkombination
— „Psoriasis kann als Prototyp einer chronisch-entzündlichen Erkrankung angesehen werden“, konstatierte Prof. Georg Schett… 
2015
2015
Cost-effectiveness of secukinumab (Cosentyx®) for the treatment of moderate to severe plaque psoriasis The NCPE has issued a recommendation regarding the cost-effectiveness of secukinumab (Cosentyx…
  • 2015
  • Corpus ID: 7027859
The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Novartis Ireland… 
Review
2015
Review
2015
Profile of secukinumab in the treatment of psoriasis: current perspectives
Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A… 
Review
2015
Review
2015
Drug updates and approvals: 2015 in review.
This article highlights important prescribing information for some drugs that received FDA approval within the past year. These… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)